Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)

BACKGROUND: Effective antiretroviral therapy reduces HIV-1 RNA levels, improves CD4 T-cell counts, and lowers the risk of opportunistic infections and malignancies. Interleukin-2 (IL-2) has been shown to increase CD4 T-cell numbers mainly by expanding CD4 cells and by prolonging their half-lives. HI...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bosch, Ronald J, Pollard, Richard B, Landay, Alan, Aga, Evgenia, Fox, Lawrence, Mitsuyasu, Ronald
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2010
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2924251/
https://ncbi.nlm.nih.gov/pubmed/20687947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-6405-7-30
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller